Assessment of orally dosed commercial silver nanoparticles on human ex vivo platelet aggregation

References

• AHA Statistical Update 2012 Heart Disease and Stroke Statistics. 2012. A report from the American Heart Association. Circulation 125. e2–e220.
   Google Scholar
• Ahmad T, Voora D, Becker RC. 2011. The pharmacogenetics of antiplatelet agents: towards personalized therapy? Clin Chimica Acta 8(10):560–571.
   Google Scholar
• Alt V, Bechert T, Steinrucke P, 2004. An in vitro assessment of the antibacterial properties and cytotoxicity of nanoparticulate silver bone cement. Biomaterials 25:4383–4391.
   PubMed Web of Science ®Google Scholar
• Bosetti M, Masse A, Tobin E, Cannas M. 2002. Silver coated materials for external fixation devices: in vitro biocompatibility and genotoxicity. Biomaterials 23:887–892.
   PubMed Web of Science ®Google Scholar
• Braydich-Stolle L, Hussain S, Schlager JJ, Hofmann MC. 2005. In vitro cytotoxicity of nanoparticles in mammalian germline stem cells. Toxicol Sci 88(2):412–419.
   Google Scholar
• Buzea C, Pacheco II, Robbie K. 2007. Nanomaterials and nanoparticles: sources and toxicity. Biointerphases 2:MR17–MR71.
   Google Scholar
• Cattaneo M, Hayward CPM, Moffat KA, Publiano MT, Liu Y, Michelson AD. 2009. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 7:1029.
   PubMed Web of Science ®Google Scholar
• Christie DJ, Avari T, Carrington LR, 2008. Platelet Function Testing by Aggregometry; Approved guideline. CLSI document H58-A 38(31):Wayne, PA, USA: Clinical and Laboratory Standards Institute.
   Google Scholar
• Clinical and Laboratory Standard Institute document H58-A. 2008. Platelet function testing by aggregometry; approved Guideline, Wayne PA, editors. Clin Lab Standards Institute.
   Google Scholar
• Dantam J, Zhu H, Stapleton FJ. 2011. Biocidal efficacy of silver impregnated contact lens storage cases. Invest Ophthalmol Vis Sci 52:51–57.
   PubMed Web of Science ®Google Scholar
• des Rieux A, Fievez V, Garinot M, Schneider Y-J, Préat V. 2006. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Controll Release 116:1–27.
   PubMed Web of Science ®Google Scholar
• Florence AT. 2007. Pharmaceutical nanotechnology: More than size. Ten topics for research. Int J Pharm 339:1–2.
   PubMed Web of Science ®Google Scholar
• Fuentes EQ, Fuentes FQ, Andrés V, Pello OM, de Mora JF, Palomo IG. 2012. Role of platelets as mediators that link information and thrombosis in atherosclerosis. Platelets; Epub ahead of print.
   Web of Science ®Google Scholar
• Geffers C, Gastmeier A, Schwab F, Groneberg K, Rüden H, Gastmeier P. 2010. Use of central venous catheter and peripheral venous catheter as risk factors for nosocomial bloodstream infection in very-low-birth-weight infants. Infect Control Hosp Epidemiol 31:395–401.
   PubMed Web of Science ®Google Scholar
• Held C, Hjemdahl P, Rehnqvist N, 1997. Haemostatic markers, inflammatory parameters and lipids in male and female patients in the Angian Prognosis Study in Stockholm (APSIS). A comparison with healthy controls. J Intern Med 241(1):59–69.
   PubMed Web of Science ®Google Scholar
• Holladay RJ, Christensen H, Moeller WD, inventors. 1999. Apparatus and method for producing antimicrobial silver solution. United States Patent 6,214,299.
   Google Scholar
• Holladay RJ, Christensen H, Moeller WD, inventors. 2003. Treatment of humans with colloidal silver composition. United States Patent 7,135,195.
   Google Scholar
• Hussain H, Jaitley V, Florence AT. 2001. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev 50:107–142.
   PubMed Web of Science ®Google Scholar
• Jun E-AH, Lim K-M, Kim K, 2011. Silver nanoparticles enhance thrombus formation through increased platelet aggregation and procoagulant activity. Nanotoxicology 5(2):157–167.
   PubMed Web of Science ®Google Scholar
• Kim K-J, Sung WS, Suh BK, Moon SK, Choi J-S. 2009. Antifungal activity and mode of action of silver nano-particles on Candida albicans. Biometals 22(2):235–242.
   PubMed Web of Science ®Google Scholar
• Margetic S. 2011. Inflammation and haemostatis. Biochem Med 22(1):49–62.
   Google Scholar
• Mills NL, Donaldson K, Hadoke PW, 2009. Adverse cardiovascular events of air pollution. Nat Clin Pract Cardiovasc Med 6:36–44.
   PubMedGoogle Scholar
• Munger MA, Radwansk P, Hadlock G, Stoddard G, Shaaban A, Falconer J, 2013. In vivo human time-exposure study of orally dosed commercial silver nanoparticles. Nanomedicine; Revised Resubmitted.
   PubMed Web of Science ®Google Scholar
• Muzi G, Locati EH, Murgia N, Ambrosio G, Abbritti G. 2004. Evaluation of the effects of occupational noxae on the cardiovascular system. Med Lav 95(2):146–157.
   Google Scholar
• O'Hagan DT. 1996. The intestinal uptake of particles and the implications for drug and antigen delivery. J Anal 189:477–482.
   Google Scholar
• Project on Emerging Nanotechnologies. 2012. Nanotech-enabled consumer products continue to rise. http//www.nanotechproject.org/news/archive/9231/. Accessed on 14 June 2012.
   Google Scholar
• Roy R, Hoover MR, Bhalla AS, 2007. Ultradilute Ag-aquasols with extraordinary bactericidal properties: Role of the system Ag-0-H20. Mat Res Innov 11:3–18.
   Web of Science ®Google Scholar
• Sabatier C, Ferrer R, Valles J. 2009. Treatment strategies for central venous catheter infections. Expert Opin Pharmacother 10:2231–2243.
   PubMed Web of Science ®Google Scholar
• Santoro CM, Duchschere NL, Grainger DW. 2007. Antimicrobial efficacy and ocular cell toxicity from silver nanoparticles. NanoBiotechnology 3(2):55–65.
   PubMedGoogle Scholar
• Schleh C, Semmler-Behnke M, Lipka J, 2012. Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration. Nanotoxicology 6(1):36–46.
   PubMed Web of Science ®Google Scholar
• Shrivastava S, Bera T, Roy A, Singh G, Ramachandrarao P, Dash D. 2007. Characterization of enhanced antibacterial effects of novel silver nanoparticles. Nanotechnology 18:225103.
   Web of Science ®Google Scholar
• Shrivastava S, Bera T, Singh SK, Singh G, Ramachandrarao P, Dash D. 2009. Characterization of antiplatelet properties of silver nanoparticles. ACS Nano 23(6):1357–1364.
   Google Scholar
• Stevens KN, Crespo-Biel O, van den Bosch EE, 2009a. The relationship between the antimicrobial effect of catheter coatings containing silver nanoparticles and the coagulation of contacting blood. Biomaterials 30:3682–3690.
   PubMed Web of Science ®Google Scholar
• Stevens KN, Knetsch ML, Sen A, Sambhy V, Koole LH. 2009b. Disruption and activation of blood platelets in contact with an antimicrobial composite coating consisting of a pyridinium polymer and AgBr nanoparticles. ACS Appl Mater Interfaces 1:2049–2054.
   PubMed Web of Science ®Google Scholar
• Stevens KNJ, Croes S, Boersma RS, 2010. Hydrophillic surface coatings with embedded biocidal silver nanoparticles and sodium heparin for central venous catheters. Biomaterials 32:1264–1269.
   PubMed Web of Science ®Google Scholar
• Wang XD, Zhang DF, Liu XB, 2012. Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance. Eur J Intern Med 23:1–48–53.
   PubMed Web of Science ®Google Scholar
• Wright SP. 1992. Adjusted P-values for simultaneous inference. Biometrics 48:1005–1013.
   Web of Science ®Google Scholar
• Xiu ZM, Zhang Q-B, Puppala HL, Colvin VL, Alvarez PJJ. 2012. Negligible particle-specific antibacterial activity of silver nanoparticles. Nano Lett 12:4271–4275.
   PubMed Web of Science ®Google Scholar